Company / Shareholders' Equity
ResMed Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$6.0B
FY2025
5-year range
$2.9B / $6.0B
FY2021-FY2025
Trend
+22.7%
vs FY2024
Sector context
#31 of 166
Health Care
What the data says
ResMed's shareholders' equity of $6.0B is higher than 81% of companies in the Health Care sector (FY2025). Shareholders' Equity has increased for 9 consecutive years, from $1.7B in FY2016 to $6.0B in FY2025.
Based on SEC 10-K filings.
$6.0B in FY2025 with a 5-year CAGR of +19.0%. Top quartile in the Health Care sector.
Improved from $4.1B to $6.0B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +21.1%
- 5-Year CAGR
- +19.0%
- 10-Year CAGR
- -
Sector benchmark
+13.6% above sector average
Key checks
Key Insights
- ResMed's shareholders' equity has grown for 9 consecutive years.
- 5-year CAGR of +19.0%, indicating consistent growth.
- In FY2025, shareholders' equity increased 22.7% year-over-year.
- Ranks #31 out of 166 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.0B | +22.7% |
| FY2024 | $4.9B | +17.8% |
| FY2023 | $4.1B | +22.9% |
| FY2022 | $3.4B | +16.5% |
| FY2021 | $2.9B | +15.6% |
| FY2020 | $2.5B | +20.5% |
| FY2019 | $2.1B | +0.6% |
| FY2018 | $2.1B | +5.0% |
| FY2017 | $2.0B | +15.7% |
| FY2016 | $1.7B | +6.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026